US equities |
SPCX $167.33 ▲+5.26% NVDA $236.25 ▲+0.98% MU $1,065.17 ▼-0.90% TSLA $377.87 ▲+1.96% MSFT $525.62 ▲+1.56% SNDK $1,709.13 ▼-0.63% INTC $117.43 ▼-1.59% META $744.16 ▲+2.21%
FinancialContent

Latest News about IVBXF

Recent news which mentions IVBXF

Sanofi, Innovent Biologics Collaborate On Cancer Treatments In China
Tickers IVBXF SNY
Tags SNY News Briefs
From Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More
Tickers ABBV AMRX BNTX BYSI
Tags AMRX ABBV FDA
From Benzinga
The Daily Biotech Pulse: BioXcel's Igalmi Gets FDA Nod, Citius Spikes On Positive Phase 3 Data, Iovance Receives Positive Regulatory Feedback For Skin Cancer Therapy
Tickers BGNE BTAI CCCC CTXR
Tags IVBXF RLMD Penny Stocks
From Benzinga
FDA Rejects Lilly's Sintilimab/Chemo Combo Therapy In First-Line Lung Cancer Setting
Tickers IVBIY IVBXF LLY
Tags News Market News FDA
From Benzinga
FDA AdComm Votes Against Lilly's Lung Cancer Drug, Sintilimab
Tickers IVBIY IVBXF LLY
Tags lung cancer Briefs Health Care
From Benzinga
Innovent Biologics, UNION therapeutics Ink Licensing Pact For Inflammatory Dermatology Candidate
Tickers IVBIY IVBXF
Tags General IVBXF Biotech
From Benzinga
Innovent Biologics, Bolt Join Forces To Develop Anti-Cancer Candidates
Tickers BOLT IVBIY IVBXF
Tags General Benzinga Biotech
From Benzinga
Innovent's Sintilimab/Chemo Regime Shows Overall Survival Benefit In Gastric Cancer
Tickers IVBIY IVBXF LLY
Tags gastric cancer Briefs Health Care
From Benzinga
Innovent - Eli Lilly's Sintilimab Combo Shows Sustained Survival Benefit In Lung Cancer Patients
Tickers IVBIY IVBXF LLY
Tags News Market News IVBIY
From Benzinga
Innovent Biologics - Incyte's Pemigatinib Application Under Review In China For Bile Duct Cancer
Tickers INCY IVBIY IVBXF
Tags IVBIY INCY FDA
From Benzinga